Bermekimab holds therapeutic potential in hidradenitis suppurativa
Interleukin (IL)-1α inhibition with bermekimab appears to be safe and effective in the treatment of moderate-to-severe hidradenitis suppurativa, inducing clinical response without raising substantial safety concerns, according to the results of a phase II trial.